GI Dynamics, Inc. Company Overview

GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically-delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts.

ASX:GID

Latest News

Press Release:

View All

Events:

View All

Publications:

Investor Contact

Main:
Janell Shields
investor@gidynamics.com
+1 781-357-3280 (U.S.)

Email Alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

* Required

*
*
 
Enter the code shown above.

Share Registry

Online investor log-in
Locked Bag A14
Sydney South NSW 1235
Australia

Quote is a for a CHESS Depositary Interests (CDI) 1 share of common stock = 50 CDIs